Analysts Set KORU Medical Systems, Inc. (NASDAQ:KRMD) Target Price at $6.13

Shares of KORU Medical Systems, Inc. (NASDAQ:KRMD) have been assigned an average rating of “Moderate Buy” from the six analysts that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $6.1250.

KRMD has been the subject of a number of analyst reports. Canaccord Genuity Group upped their price objective on shares of KORU Medical Systems from $5.00 to $6.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Craig Hallum reiterated a “buy” rating and issued a $7.00 price target on shares of KORU Medical Systems in a research note on Tuesday, January 13th. Lake Street Capital increased their price target on KORU Medical Systems from $6.00 to $8.00 and gave the company a “buy” rating in a report on Monday, December 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of KORU Medical Systems in a report on Thursday, January 22nd. Finally, Wall Street Zen raised KORU Medical Systems from a “buy” rating to a “strong-buy” rating in a research report on Monday, January 12th.

KORU Medical Systems Price Performance

KRMD stock opened at $4.56 on Thursday. The firm has a market cap of $211.23 million, a P/E ratio of -57.00 and a beta of 0.44. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.92 and a current ratio of 2.48. KORU Medical Systems has a 1 year low of $1.86 and a 1 year high of $6.61. The stock has a 50-day simple moving average of $5.64 and a 200-day simple moving average of $4.68.

Institutional Investors Weigh In On KORU Medical Systems

Institutional investors have recently modified their holdings of the stock. Globeflex Capital L P bought a new position in shares of KORU Medical Systems during the fourth quarter worth about $151,000. Goldman Sachs Group Inc. raised its stake in KORU Medical Systems by 32.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 169,349 shares of the company’s stock valued at $984,000 after buying an additional 41,488 shares in the last quarter. Geode Capital Management LLC lifted its holdings in KORU Medical Systems by 1.6% during the 4th quarter. Geode Capital Management LLC now owns 1,022,860 shares of the company’s stock worth $5,944,000 after buying an additional 16,062 shares during the last quarter. Baader Bank Aktiengesellschaft bought a new position in KORU Medical Systems during the 4th quarter worth approximately $174,000. Finally, Simcoe Capital LLC acquired a new position in shares of KORU Medical Systems in the 4th quarter worth approximately $3,921,000. Institutional investors and hedge funds own 58.60% of the company’s stock.

About KORU Medical Systems

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.